Kushanda Kwenguva Yakareba kweCD19 CAR T-Cell Therapy muKurapa Yakadzokazve / Refractory Acute Lymphoblastic Leukemia

Mukufambira mberi kwakakosha mumunda wehematology, ongororo ichangobva kuitika yakaratidza kushanda kwenguva refu kweCD19 chimeric antigen receptor (CAR) T-cell therapy mune varwere vanotambura nekudzokazve / refractory acute lymphoblastic leukemia (ALL) post-allogeneic hematopoietic stem. cell transplantation (allo-HSCT). Chidzidzo ichi, icho chinotevera varwere kwenguva yakareba, chinopa kuongororwa kwakadzama kwezvakabuda, zvichipa ruzivo rwakakosha mukusimba uye kuchengetedzeka kwekurapa uku.

Chidzidzo ichi chakanyatso kuronda varwere vaive vaitwa CD19 CAR T-cell therapy mushure mekusangana nekudzoka kweZVESE zvichitevera allo-HSCT. Zvigumisiro zvinovimbisa, zvichiratidza kuti chikamu chikuru chevarwere vakawana kuregererwa kwakakwana, nemhinduro dzakaramba dzichionekwa mumakore. Tsvagiridzo iyi haingotsigire kugona kwekurapa kweCAR T-cell therapy asi zvakare inoratidza chiitiko chakakosha mukurapa hematological malignancies, kunyanya kune avo vane maitiro mashoma ekurapwa.

Uyezve, chidzidzo ichi chinotarisa mune yakachengeteka chimiro chekurapa, ichitaura zvinogoneka mhedzisiro, izvo zvaienderana nezvakawanikwa kare. Izvi zvinosimbisa kuvimba kuri kukura muCAR T-cell therapy semushonga unoshanda uye unoshanda wekudzoreredza/kuramba ZVESE, kunyanya mumashure ekutapurirana.

Sezvo munda we immunotherapy uchiramba uchishanduka, chidzidzo ichi chinoshanda sechiedza chetariro kune varwere nevarapi vehutano zvakafanana, vachivimbisa ramangwana iro varwere vazhinji vanogona kuwana kuregererwa kwenguva refu. Zvakawanikwa hazvingobatsiri kukura kwehumbowo hunotsigira CAR T-cell therapy asi zvakare inovhura nzira yekumwe tsvagiridzo yekuwedzera nekuwedzera kushandiswa kwayo mumakiriniki.

Nekubudirira uku, nharaunda yezvekurapa inoswedera pedyo nekushandura nzvimbo yekurapa yehematological malignancies, ichipa tariro itsva kune varwere vari kurwisa mamiriro aya akaoma.